<SEC-DOCUMENT>0001558370-20-010781.txt : 20200820
<SEC-HEADER>0001558370-20-010781.hdr.sgml : 20200820
<ACCEPTANCE-DATETIME>20200820172928
ACCESSION NUMBER:		0001558370-20-010781
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200820
FILED AS OF DATE:		20200820
DATE AS OF CHANGE:		20200820

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENMAB A/S
		CENTRAL INDEX KEY:			0001434265
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38976
		FILM NUMBER:		201120915

	BUSINESS ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000

	MAIL ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tmb-20200820x6k.htm
<DESCRIPTION>6-K
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 8/20/2020 09:29:21 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Washington,&#160;D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">FORM&#160;6-K</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE&#160;13a-16 OR&#160;15d-16</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">FOR THE&#160;MONTH OF AUGUST 2020</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;white-space:pre-wrap;">COMMISSION FILE NUMBER 001-38976  </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">Genmab A/S<br></b><font style="background-color:#ffffff;color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">(Exact name of Registrant as specified in its charter)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Kalvebod Brygge 43</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">1560 Copenhagen V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Denmark</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">+45 70 20 27 28<br></b><font style="background-color:#ffffff;color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">(Address of principal executive offices)</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or&#160;Form&#160;40-F.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Form&#160;20-F&#160;</font><font style="font-family:'Times New Roman';">&#8999;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      Form&#160;40-F&#160;</font><font style="font-family:'Times New Roman';font-size:10pt;">&#9723;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Yes&#160;</font><font style="font-family:'Times New Roman';font-size:10pt;">&#9723;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      No&#160;</font><font style="font-family:'Times New Roman';">&#8999;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Yes&#160;</font><font style="font-family:'Times New Roman';font-size:10pt;">&#9723;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      No&#160;</font><font style="font-family:'Times New Roman';">&#8999;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="background-color:#ffffff;">This report on Form&#160;6-K&#160;shall be deemed to be&#160;</font>incorporated by reference<font style="background-color:#ffffff;">&#160;in Genmab A/S&#8217;s registration statements on&#160;</font><font style="background-color:#ffffff;">Form&#160;S-8</font><font style="background-color:#ffffff;">&#160;(File&#160;No.&#160;333-232693)&#160;and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">SIGNATURE</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">nthony</p></div></div></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GENMAB A/S</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">BY:</font></p></td><td style="vertical-align:bottom;width:45.3%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">/s/ Anthony Pagano</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Name: Anthony Pagano</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Title: Executive Vice President &amp; Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">DATE: August 20, 2020</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">EXHIBIT&#160;INDEX</b></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:-1.1127167%;width:102.22%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">O</font></p></div></div></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit</u></p></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Description of Exhibit</u></p></td></tr><tr><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Company Announcement Dated August 20, 2020: Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX&#174; (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20200820xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 8/20/2020 09:29:18 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><img src="tmb-20200820xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;">Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9.75pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;"> (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">Company Announcement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">DARZALEX</b><sup style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:bold;text-align:left;vertical-align:top;">&#174;</sup><b style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;white-space:pre-wrap;"> (daratumumab) approved by U.S. FDA in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who have received one to three previous lines of therapy  </b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Approval based on the Phase 3 CANDOR study</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Approval marks eighth U.S. FDA approval for DARZALEX</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Copenhagen, Denmark; August 20, 2020 &#8211; Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (U.S. FDA) has approved the use of DARZALEX</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;white-space:pre-wrap;"> (daratumumab) in combination with carfilzomib and dexamethasone (DKd) for the treatment of adult patients with relapsed/refractory multiple myeloma who have received one to three previous lines of therapy.  </b><font style="font-family:'Arial','Helvetica','sans-serif';">A</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"> </b><font style="font-family:'Arial','Helvetica','sans-serif';">supplemental Biologics License Application (sBLA) for this indication was submitted by Genmab&#8217;s licensing partner, Janssen Biotech, Inc. (Janssen), in February 2020. In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;We are extremely pleased that multiple myeloma patients in the U.S. will now have yet another treatment option as this is the eighth overall U.S. FDA approval for DARZALEX and the fifth in the relapsed/refractory setting. In addition, DARZALEX is now the first CD38 antibody approved for use in combination with carfilzomib,&#8221; said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The combination has been approved in two carfilzomib dosing regimens, 70 mg/m</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">2</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> once weekly and 56 mg/m</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">2</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> twice weekly, based on positive results from the Phase 3 CANDOR and Phase 1b EQUULEUS studies</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">. </b><font style="font-family:'Arial','Helvetica','sans-serif';">CANDOR was an Amgen-sponsored study, co-funded by Janssen Research &amp; Development, LLC. EQUULEUS was sponsored by Janssen Research &amp; Development, LLC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About the CANDOR study</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The Phase 3 trial (NCT03158688) was a randomized, open-label study that included 466 patients with multiple myeloma who had relapsed after 1 to 3 prior therapies. Patients were randomized to receive either DKd or carfilzomib and dexamethasone (Kd) alone. In the daratumumab treatment arm, patients received 8 milligrams per kilogram (mg/kg) on days 1 and 2 of cycle 1, then 16 mg/kg once weekly for the remaining doses of the first 2 cycles, then every 2 weeks for 4 cycles (cycles 3 to 6), and then every 4 weeks for the remaining cycles or until disease progression. In both treatment arms carfilzomib was dosed twice weekly (20 mg/m</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">2</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> on cycle 1 days 1 and 2 and 56 mg/m</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">2</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> beginning on cycle 1 day 8 and thereafter) and dexamethasone was given weekly (40 mg orally or via IV infusion). The primary endpoint of the study was progression free survival (PFS). </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About the EQUULEUS (MMY1001) Study </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The Phase 1b EQUULEUS (NCT01998971) study was an open label, multi-cohort trial that evaluated the safety, tolerability, and dose regimen of daratumumab when administered in combination with various treatment regimens for the treatment of multiple myeloma. Among the regiments evaluated, the combination of DKd compared to Kd alone was studied in 85 patients with relapsed/refractory multiple myeloma who had received one to three prior lines of therapy using a once-weekly dosing regimen. DKd was evaluated at a starting dose of 20 mg/m2, which was increased to 70 mg/m2 on Cycle 1, Day 8 and onward.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:12pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 38</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 1/4</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">21560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com </p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">LEI Code 529900MTJPDPE4MHJ122</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><img src="tmb-20200820xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;">Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9.75pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;"> (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a name="_Hlk34744061"></a><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About multiple myeloma</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="background-color:#ffffff;font-family:'Arial','Helvetica','sans-serif';">Multiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excess proliferation of plasma cells.</font><sup style="background-color:#ffffff;font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">1</sup><font style="background-color:#ffffff;font-family:'Arial','Helvetica','sans-serif';"> Multiple myeloma is the third most common blood cancer in the U.S., after leukemia and lymphoma.</font><sup style="background-color:#ffffff;font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">2</sup><font style="background-color:#ffffff;font-family:'Arial','Helvetica','sans-serif';"> Approximately 26,000 new patients were expected to be diagnosed with multiple myeloma and approximately 13,650 people were expected to die from the disease in the U.S. in 2018.</font><sup style="background-color:#ffffff;font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">3</sup><font style="background-color:#ffffff;font-family:'Arial','Helvetica','sans-serif';"> Globally, it was estimated that 160,000 people were diagnosed and 106,000 died from the disease in 2018.</font><sup style="background-color:#ffffff;font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">4</sup><font style="background-color:#ffffff;font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;">  While some patients with multiple myeloma have no symptoms at all, most patients are diagnosed due to symptoms which can include bone problems, low blood counts, calcium elevation, kidney problems or infections.</font><sup style="background-color:#ffffff;font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">5</sup><font style="background-color:#ffffff;font-family:'Arial','Helvetica','sans-serif';"> </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About DARZALEX</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> </font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">(daratumumab)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">DARZALEX</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> (daratumumab) has become a backbone therapy in the treatment of multiple myeloma. DARZALEX intravenous infusion is indicated for the treatment of adult patients in the United States: in combination with carfilzomib and dexamethasone for the treatment of  patients with relapsed/refractory multiple myeloma who have received one to three previous lines of therapy; in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">6 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (U.S. FDA) approval to treat multiple myeloma. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">DARZALEX is indicated for the treatment of adult patients in Europe via intravenous infusion or subcutaneous administration: in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">7</sup><font style="font-family:'Arial','Helvetica','sans-serif';">. Daratumumab is the first subcutaneous CD38 antibody approved in Europe for the treatment of multiple myeloma. The option to split the first infusion of DARZALEX over two consecutive days has been approved in both Europe and the U.S. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;">In Japan, DARZALEX intravenous infusion is approved for the treatment of adult patients: in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of relapsed or refractory multiple myeloma.  DARZALEX is the first human CD38 monoclonal antibody to reach the market in the United States, Europe and Japan. For more information, visit </font><font style="font-family:'Arial','Helvetica','sans-serif';">www.DARZALEX.com</font><font style="font-family:'Arial','Helvetica','sans-serif';">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:12pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 38</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 2/4</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">21560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com </p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">LEI Code 529900MTJPDPE4MHJ122</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><img src="tmb-20200820xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;">Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9.75pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;"> (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a name="_Hlk39238089"></a><font style="font-family:'Arial','Helvetica','sans-serif';">DARZALEX</font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> FASPRO</i><font style="font-family:'Arial','Helvetica','sans-serif';">&#8482; (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, is approved in the United States for the treatment of adult patients with multiple myeloma: in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for ASCT and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy; in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and as monotherapy, in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">8 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">DARZALEX</font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> FASPRO</i><font style="font-family:'Arial','Helvetica','sans-serif';"> is the first subcutaneous CD38 antibody approved in the U.S. for the treatment of multiple myeloma.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. Daratumumab triggers a person&#8217;s own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">6,9,10,11,12</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a name="_Hlk39238148"></a><font style="font-family:'Arial','Helvetica','sans-serif';">Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A comprehensive clinical development program for daratumumab is ongoing, including multiple Phase III studies in smoldering, relapsed and refractory and frontline multiple myeloma settings. Additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases in which CD38 is expressed, such as amyloidosis and T-cell acute lymphocytic leukemia (ALL). Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA for certain indications of multiple myeloma, including as a monotherapy for heavily pretreated multiple myeloma and in combination with certain other therapies for second-line treatment of multiple myeloma.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About Genmab </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of the following approved antibodies: DARZALEX</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Kesimpta</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> (subcutaneous ofatumumab, under agreement with Novartis AG), for the treatment of adults with relapsing forms of multiple sclerosis in the U.S. and TEPEZZA</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174; </sup><font style="font-family:'Arial','Helvetica','sans-serif';">(teprotumumab, under agreement with Roche granting sublicense to Horizon Therapeutics plc) for the treatment of thyroid eye disease in the U.S. A subcutaneous formulation of daratumumab, known as DARZALEX FASPRO&#8482; (daratumumab and hyaluronidase-fihj) in the U.S., has been approved in the U.S. and Europe for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy, Arzerra</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> (ofatumumab, under agreement with Novartis AG), approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab&#39;s technology base consists of validated and proprietary next generation antibody technologies - the DuoBody</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> platform for generation of bispecific antibodies, the HexaBody</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> platform, which creates effector function enhanced antibodies, the HexElect</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.<br></font><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:12pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 38</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 3/4</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">21560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com </p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">LEI Code 529900MTJPDPE4MHJ122</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><img src="tmb-20200820xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;">Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9.75pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;"> (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Contact:</b></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><font style="font-family:'Arial','Helvetica','sans-serif';">Marisol Peron, Corporate Vice President, Communications &amp; Investor Relations </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">T: +1 609 524 0065; E: mmp@genmab.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">For Investor Relations: </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Andrew Carlsen, Senior Director, Investor Relations</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">T: +45 3377 9558; E: acn@genmab.com </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><font style="font-size:10pt;"><a name="_Hlk34743654"></a></font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">This Company Announcement contains forward looking statements. The words &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;anticipate&#8221;, &#8220;intend&#8221; and &#8220;plan&#8221; and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab&#8217;s most recent financial reports, which are available on </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">www.genmab.com</i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> and the risk factors included in Genmab&#8217;s </i><font style="font-size:10pt;"><a name="_Hlk35592020"></a></font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">most recent Annual Report on Form 20-F </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">and other filings </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">with the U.S. Securities and Exchange Commission (SEC), which are available at</i><i style="font-size:10pt;font-style:italic;"> www.sec.gov</i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><font style="font-size:10pt;"><a name="_Hlk39589183"></a></font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">Genmab A/S and/or its subsidiaries own the following trademarks: Genmab</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; the Y-shaped Genmab logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; Genmab in combination with the Y-shaped Genmab logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; HuMax</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; DuoBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; DuoBody in combination with the DuoBody logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; HexaBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">;</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;"> </sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">HexaBody in combination with</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;"> </sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">the HexaBody logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; DuoHexaBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; HexElect</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; and UniBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">. Arzerra</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> and Kesimpta</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174; </sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">are trademarks of Novartis AG or its affiliates. DARZALEX</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> and DARZALEX FASPRO&#8482; are trademarks of Janssen Pharmaceutica NV. TEPEZZA&#8482; is a trademark of Horizon Therapeutics plc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">1</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> American Cancer Society. &quot;Multiple Myeloma Overview.&quot; Available at </font><font style="font-family:'Arial','Helvetica','sans-serif';">http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-what-is-multiple-myeloma</font><font style="font-family:'Arial','Helvetica','sans-serif';">.Accessed June 2016.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">2 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">National Cancer Institute. &quot;A Snapshot of Myeloma.&quot; Available at www.cancer.gov/research/progress/snapshots/myeloma. Accessed June 2016. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">3 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">Globocan 2018. United States of America Fact Sheet. Available at http://gco.iarc.fr/today/data/factsheets/840-united-states-of-america-fact-sheets.pdf.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">4 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">Globocan 2018. World Fact Sheet. Available at </font><font style="font-family:'Arial','Helvetica','sans-serif';">http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf. Accessed December 2018</font><font style="font-family:'Arial','Helvetica','sans-serif';">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">5 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">American Cancer Society. &quot;How is Multiple Myeloma Diagnosed?&quot; http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-diagnosis. Accessed June 2016</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">6</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> DARZALEX</font><font style="font-family:'Arial','Helvetica','sans-serif';"> Prescribing information, September 2019. Available at: </font><font style="font-family:'Arial','Helvetica','sans-serif';">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761036s024lbl.pdf Last accessed September 2019</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">7</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> DARZALEX Summary of Product Characteristics, available at </font><font style="font-family:'Arial','Helvetica','sans-serif';">https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex</font><font style="font-family:'Arial','Helvetica','sans-serif';"> Last accessed June 2020</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">8 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">DARZALEX </font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">FASPRO</i><font style="font-family:'Arial','Helvetica','sans-serif';"> Prescribing information, May 2020. Available at: </font><font style="font-family:'Arial','Helvetica','sans-serif';">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761145s000lbl.pdf</font><font style="font-family:'Arial','Helvetica','sans-serif';"> Last accessed May 2020</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">9 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">De Weers, M et al. </font><font style="font-family:'Arial','Helvetica','sans-serif';">Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">10 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">11 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">12 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">Jansen, JH &#160;et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking.&#160;Blood. 2012; 120(21): abstract 2974.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:12pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 38</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 4/4</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">21560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com </p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">LEI Code 529900MTJPDPE4MHJ122</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tmb-20200820xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20200820xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !: 2\# 2(  A$! Q$!_\0
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2IJ5;KE2LC;#87EE[6<N:1__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
